NCT05010369

Brief Summary

Lymphoma diagnosis often involves removal and biopsy of one or more lymph nodes. Many (around half) of these diagnostic procedures show that no cancer is present, hence unnecessary removal results in numerous side effects and complications. The procedure is also highly invasive. The investigators have already shown that it is possible to tell the difference between healthy and diseased tissue in the laboratory by looking at the light emitted by tissue when a low power laser is shone on to it. The investigators intend to use this technique, known as "Raman Spectroscopy" (RS) to tell if tissue in the node is cancerous or healthy. By combining RS with a fine needle, the technique can target tissues below the skin with minimal invasion. Our needle will provide the clinician with instant diagnosis without the delay and cost of a laboratory analysis by pathologists. The investigators have designed a probe that slides through a fine needle, guided by ultrasound, to the lymph node. The space between the two needles provides space for cell aspirate. The investigators propose to measure spectra from excess lymph node biopsy samples taken during standard routine diagnostic biopsy. The investigators are also interested to see if they can successfully extract a fine needle aspiration (FNA) biopsy sample using the device, as well as record a RS measurement. If successful this would ease clinical adoption as the study could run in parallel with existing standard routine clinical practice, using just one device. This study will evaluate the new device on half a lymph node that will be excised and snap-frozen during a routine surgical biopsy, to gather data for submission of approvals for an in-vivo study to follow.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
14

participants targeted

Target at below P25 for not_applicable lymphoma

Timeline
Completed

Started Sep 2024

Shorter than P25 for not_applicable lymphoma

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 20, 2021

Completed
3 months until next milestone

First Posted

Study publicly available on registry

August 18, 2021

Completed
3 years until next milestone

Study Start

First participant enrolled

September 2, 2024

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 26, 2025

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 17, 2025

Completed
Last Updated

June 26, 2025

Status Verified

June 1, 2025

Enrollment Period

6 months

First QC Date

May 20, 2021

Last Update Submit

June 20, 2025

Conditions

Keywords

RamanLymphoma

Outcome Measures

Primary Outcomes (1)

  • Safety of in vivo measurement of lymph nodes using Raman spectroscopy to acquire diagnostic quality spectra

    Testing of the device for clinical application during surgery to demonstrate its use is safe and that is able to acquire diagnostic-quality spectra in less than 5 seconds from lymph nodes.

    3 years

Secondary Outcomes (1)

  • Safe in vivo measurement of lymph nodes using Raman spectroscopy to acquire diagnostic quality spectra

    3 years

Study Arms (5)

non-hodgkin lymphoma

EXPERIMENTAL

patients diagnosed with non-hodgkin lymphoma

Diagnostic Test: spectroscopic measurementDiagnostic Test: FNA biopsyDiagnostic Test: histopathology and cytology

hodgkin lymphoma

EXPERIMENTAL

patients diagnosed with hodgkin lymphoma

Diagnostic Test: spectroscopic measurementDiagnostic Test: FNA biopsyDiagnostic Test: histopathology and cytology

squamous cell carcinoma

EXPERIMENTAL

patients diagnosed with squamous cell carcinoma

Diagnostic Test: spectroscopic measurementDiagnostic Test: FNA biopsyDiagnostic Test: histopathology and cytology

reactive

EXPERIMENTAL

patients diagnosed with a reactive (non-cancerous) lymph node

Diagnostic Test: spectroscopic measurementDiagnostic Test: FNA biopsyDiagnostic Test: histopathology and cytology

other

EXPERIMENTAL

none of the above. Other cancer and non-cancer conditions

Diagnostic Test: spectroscopic measurementDiagnostic Test: FNA biopsyDiagnostic Test: histopathology and cytology

Interventions

measurement of the tissue with spectroscopy

Also known as: raman, infra red
hodgkin lymphomanon-hodgkin lymphomaotherreactivesquamous cell carcinoma
FNA biopsyDIAGNOSTIC_TEST

a fine needle aspiration (FNA) biopsy will be taken

Also known as: fine needle aspiration biopsy
hodgkin lymphomanon-hodgkin lymphomaotherreactivesquamous cell carcinoma

Histopathology and cytology will be performed on the samples

hodgkin lymphomanon-hodgkin lymphomaotherreactivesquamous cell carcinoma

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients undergoing biopsy or excision of more than one lymph node as part of their routine clinical care within Gloucestershire Hospitals NHS Foundation Trust.
  • Patients undergoing lymphadenectomy as part of routine treatment

You may not qualify if:

  • Patients requiring biopsy of only one lymph node
  • Patients unable to consent to the study due to communication difficulties
  • Patients unable to consent to the study due to lack of capacity

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gloucestershire Hospitals NHS Foundation Trust

Gloucester, Gloucestershire, GL1 3NN, United Kingdom

Location

MeSH Terms

Conditions

LymphomaHead and Neck Neoplasms

Interventions

Nonlinear Optical MicroscopyBiopsy, Fine-NeedleCytological Techniques

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesNeoplasms by Site

Intervention Hierarchy (Ancestors)

MicroscopyDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisInvestigative TechniquesBiopsy, NeedleBiopsyCytodiagnosisClinical Laboratory TechniquesSpecimen HandlingDiagnostic Techniques, SurgicalSurgical Procedures, OperativePunctures

Study Officials

  • Nick Stone

    University of Exeter

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DEVICE FEASIBILITY
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 20, 2021

First Posted

August 18, 2021

Study Start

September 2, 2024

Primary Completion

February 26, 2025

Study Completion

June 17, 2025

Last Updated

June 26, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Unique study number and MRN (medical records number) (hospital number)

Locations